Charting the Course in TR Care

Innoventric's innovation is built on the firm belief that the heterotopic,
cross-caval approach is key to improving TR treatment and extending
care to the often-overlooked patient population.

Innoventric holds a strong patent portfolio for cross-caval
technologies and continuously innovates to broaden the scope of the
solutions it can offer patients.
Innoventric's innovation is built on the firm belief that the heterotopic, cross-caval approach is key to improving TR treatment and extending care to the often-overlooked patient population.

Innoventric holds a strong patent portfolio for cross-caval technologies and continuously innovates to broaden the scope of the solutions it can offer patients.

Trillium™

Trillium™ is the first-of-its-kind cross-caval device, uniquely designed to address TR in a broad patient population. Featuring multiple valves with a novel hinge design, it serves as a particularly beneficial solution in large and tortuous anatomies.

 

Following a successful First-in-Human study in Europe and an Early Feasibility Study in the U.S. and Germany, the Trillium™ Early Feasibility Study is now extended and continues to enroll patients.

Koala™

A cross-caval docking station,

Koala™ is designed for anchoring in both
the SVC and IVC, facilitating the placement of an off-the-shelf valve.

 

Status: Several compassionate cases performed in the EU.

Unica™

Building upon the success of Trillium™, our aim with Unica™ is to extend the spectrum of care to an even broader patient population by adding patients with even smaller anatomies. Unica’s bare metal center structure enables future transseptal procedures, and its intra-luminal valves are designed to allow future valve in-valve procedures, if required.

 

Status: Several compassionate cases performed in the EU and Canada.

Publications

All Trillium™ Koala™ Unica™
16/11/2023

Implantation of a Stent Graft System for Torrential Tricuspid Regurgitation: A First-in-Human Experience

We report on a patient with torrential tricuspid regurgitation (TR) who underwent the worldwide first-in-human implantation of the Koala device (Innoventric) (Figure 1).
28/12/2023

First-in-Human Treatment of Severe Tricuspid Regurgitation Using a Novel Cross-Caval Heterotopic Device

A 79-year-old woman, previously surgically treated for mitral and aortic valve replacement, experienced recurrent torrential tricuspid regurgitation after 2 transcatheter edge-to-edge repair procedures. Heart team assessment deemed the patient high risk for redo surgery and excluded transcatheter edge-to-edge repair and orthotopic replacement. The patient was then scheduled for a novel cross-caval device implantation.
01/01/2024

UNICA − a novel single-stent, double-valve, heterotopic, cross-caval approach for severe tricuspid insufficiency

We present an 85-year-old female patient in New York Heart Association (NYHA) Functional Class III, with preserved left ventricular ejection fraction, who experienced recurrent valvular heart failure hospitalisations and cardiac decompensation due to severe, torrential tricuspid regurgitation (TR) with a large coaptation defect (grade 5/5, 16 mm gap) (Figure 1A, Moving image 1). She also […]
09/06/2025

Heterotopic Crosscaval Transcatheter Tricuspid Valve Replacement for Patients with Tricuspid…

Tricuspid regurgitation (TR) is associated with significant morbidity and mortality but foremost a potpourri of severe symptoms that range from…conventional heart failure symptoms such as dyspnea and limited functional capacity to malnutrition, abdominal bloating, and ascites associated with systemic effects of TR.1
26/10/2025

Innovation in TTVR

Trillium™ EFS results were presented at TCT conference Heterotopic TTVR in Patients with Severe Tricuspid Regurgitation: Initial Results of the Trillium™ EFS
09/06/2025

Heterotopic Crosscaval Transcatheter Tricuspid Valve Replacement for Patients with Tricuspid…

Tricuspid regurgitation (TR) is associated with significant morbidity and mortality but foremost a potpourri of severe symptoms that range from…conventional heart failure symptoms such as dyspnea and limited functional capacity to malnutrition, abdominal bloating, and ascites associated with systemic effects of TR.1
26/10/2025

Innovation in TTVR

Trillium™ EFS results were presented at TCT conference Heterotopic TTVR in Patients with Severe Tricuspid Regurgitation: Initial Results of the Trillium™ EFS
16/11/2023

Implantation of a Stent Graft System for Torrential Tricuspid Regurgitation: A First-in-Human Experience

We report on a patient with torrential tricuspid regurgitation (TR) who underwent the worldwide first-in-human implantation of the Koala device (Innoventric) (Figure 1).
28/12/2023

First-in-Human Treatment of Severe Tricuspid Regurgitation Using a Novel Cross-Caval Heterotopic Device

A 79-year-old woman, previously surgically treated for mitral and aortic valve replacement, experienced recurrent torrential tricuspid regurgitation after 2 transcatheter edge-to-edge repair procedures. Heart team assessment deemed the patient high risk for redo surgery and excluded transcatheter edge-to-edge repair and orthotopic replacement. The patient was then scheduled for a novel cross-caval device implantation.
01/01/2024

UNICA − a novel single-stent, double-valve, heterotopic, cross-caval approach for severe tricuspid insufficiency

We present an 85-year-old female patient in New York Heart Association (NYHA) Functional Class III, with preserved left ventricular ejection fraction, who experienced recurrent valvular heart failure hospitalisations and cardiac decompensation due to severe, torrential tricuspid regurgitation (TR) with a large coaptation defect (grade 5/5, 16 mm gap) (Figure 1A, Moving image 1). She also […]
Skip to content